NCT00228163 - Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Multiple Sclerosis

Interventions

DRUG

teriflunomide (HMR1726)

tablet, oral administration once daily.

Trial Locations (16)

13385

Investigational Site Number 30, Marseille

34000

Investigational Site Number 23, Montpellier

35033

Investigational Site Number 27, Rennes

63003

Investigational Site Number 24, Clermont-Ferrand

69394

Investigational Site Number 21, Lyon

T2N 2T9

Investigational Site Number 16, Calgary

B3H 1V7

Investigational Site Number 10, Halifax

N6A 5A5

Investigational Site Number 15, London

H2L 4M1

Investigational Site Number 12, Montreal

H3A 2B4

Investigational Site Number 11, Montreal

K1H 8L6

Investigational Site Number 13, Ottawa

G1J 1Z4

Investigational Site Number 18, Québec

M5B 1W8

Investigational Site Number 14, Toronto

V6T 2B5

Investigational Site Number 17, Vancouver

R3E 3N4

Investigational Site Number 19, Winnipeg

06002

Investigational Site Number 28, Nice